BR0109011A - Composto, processo para preparação e uso do mesmo, método para produzir um efeito inibidor de ibat em um animal de sangue quente, e, composição farmacêutica - Google Patents

Composto, processo para preparação e uso do mesmo, método para produzir um efeito inibidor de ibat em um animal de sangue quente, e, composição farmacêutica

Info

Publication number
BR0109011A
BR0109011A BR0109011-9A BR0109011A BR0109011A BR 0109011 A BR0109011 A BR 0109011A BR 0109011 A BR0109011 A BR 0109011A BR 0109011 A BR0109011 A BR 0109011A
Authority
BR
Brazil
Prior art keywords
compound
producing
preparation
pharmaceutical composition
warm
Prior art date
Application number
BR0109011-9A
Other languages
English (en)
Inventor
Ingemar Starke
Dahlstrom Michael
David Blomberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0109011A publication Critical patent/BR0109011A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSTO, PROCESSO PARA PREPARAçãO E USO DO MESMO, MéTODO PARA PRODUZIR UM EFEITO INIBIDOR DE IBAT EM UM ANIMAL DE SANGUE QUENTE, E, COMPOSIçãO FARMACêUTICA". A presente invenção refere-se a compostos de fórmula (I) em que R^ 1^ e R^ 2^ são, independentemente, selecionados de C~ 1-6~alquila; um entre R^ 4^ e R^ 5^ é um grupo de fórmula (IA) R^ 3^, R^ 6^, R^ 7^, R^ 8^, R^ 9^, R^ 10^ e R^ 11^ e o outro do grupo R^ 4^ e R^ 5^ é como definido no interior do relatório, sais farmaceuticamente aceitáveis, solvatos, solvatos de tais sais e pró-drogas dos mesmos e seu uso como inibidores de transporte de ácido biliar ileal (IBAT) para o tratamento de hiperlipemia. São também descritos processos para sua fabricação e composições farmacêuticas que os contêm.
BR0109011-9A 2000-03-08 2001-03-05 Composto, processo para preparação e uso do mesmo, método para produzir um efeito inibidor de ibat em um animal de sangue quente, e, composição farmacêutica BR0109011A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0000772A SE0000772D0 (sv) 2000-03-08 2000-03-08 Chemical compounds
PCT/GB2001/000909 WO2001066533A1 (en) 2000-03-08 2001-03-05 1,5-benzothiazepines and their use as hypolipidaemics

Publications (1)

Publication Number Publication Date
BR0109011A true BR0109011A (pt) 2003-06-03

Family

ID=20278738

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0109011-9A BR0109011A (pt) 2000-03-08 2001-03-05 Composto, processo para preparação e uso do mesmo, método para produzir um efeito inibidor de ibat em um animal de sangue quente, e, composição farmacêutica

Country Status (17)

Country Link
US (1) US6906058B2 (pt)
EP (1) EP1263747B1 (pt)
JP (1) JP5204361B2 (pt)
KR (1) KR20020079990A (pt)
CN (1) CN1416425A (pt)
AT (1) ATE283266T1 (pt)
AU (2) AU3755601A (pt)
BR (1) BR0109011A (pt)
CA (1) CA2401055A1 (pt)
DE (1) DE60107395T2 (pt)
IL (1) IL151296A0 (pt)
MX (1) MXPA02008600A (pt)
NO (1) NO20024217L (pt)
NZ (1) NZ520951A (pt)
SE (1) SE0000772D0 (pt)
WO (1) WO2001066533A1 (pt)
ZA (1) ZA200206739B (pt)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG26979A (en) * 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) * 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) * 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
PL216023B1 (pl) 2001-09-08 2014-02-28 Astrazeneca Ab Pochodna benzotiadiazepiny, kompozycja farmaceutyczna zawierajaca pochodna benzotiadiazepiny oraz zastosowania pochodnej benzotiadiazepiny
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0201850D0 (en) * 2002-01-26 2002-03-13 Astrazeneca Ab Therapeutic treatment
AU2003203482B2 (en) 2002-04-09 2005-06-02 Syngenta Participations Ag Process for the preparation of cyclic diketones
GB0209467D0 (en) * 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) * 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
EP1517883B8 (en) * 2002-06-20 2008-05-21 AstraZeneca AB Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
GB0304194D0 (en) * 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
GB0314131D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
WO2006085149A2 (en) 2004-12-22 2006-08-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
AR057828A1 (es) * 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
KR101608445B1 (ko) 2006-10-12 2016-04-01 비에이치아이 리미티드 파트너쉽 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클
ES2445049T3 (es) 2007-03-08 2014-02-27 Albireo Ab Derivados del ácido 3-fenilpropiónico y su uso en el tratamiento de la enfermedad inflamatoria intestinal
EP2367554A4 (en) * 2008-11-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid reflux inhibitor for the treatment of obesity and diabetes
EP3593802A3 (en) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
ES2586931T3 (es) 2010-11-04 2016-10-19 Albireo Ab Inhibidores de IBAT para el tratamiento de enfermedades hepáticas
RU2619215C2 (ru) 2010-11-08 2017-05-12 Альбирео Аб Фармацевтическая комбинация, включающая ibat-ингибитор и связующее желчной кислоты
KR102051031B1 (ko) 2011-10-28 2019-12-02 루메나 파마수티컬즈, 인코포레이티드 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
BR112014010223B8 (pt) 2011-10-28 2021-02-23 Lumena Pharmaceuticals Llc uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
KR20160003664A (ko) 2013-03-15 2016-01-11 루메나 파마수티컬즈, 인코포레이티드 바렛 식도 및 위식도 역류 질환 치료용 담즙산 재순환 억제제
EP2968230A2 (en) 2013-03-15 2016-01-20 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CN106659726A (zh) 2014-06-25 2017-05-10 Ea制药株式会社 固体制剂及其着色防止或着色减少方法
KR101674806B1 (ko) * 2014-10-20 2016-11-10 씨제이헬스케어 주식회사 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
EP3413878B1 (en) 2016-02-09 2021-04-14 Albireo AB Oral cholestyramine formulation and use thereof
EP3413875B1 (en) 2016-02-09 2020-01-29 Albireo AB Cholestyramine pellets and methods for preparation thereof
EP3413877B1 (en) 2016-02-09 2021-04-07 Albireo AB Oral cholestyramine formulation and use thereof
KR101844184B1 (ko) * 2017-07-21 2018-04-02 씨제이헬스케어 주식회사 아미노알킬벤조티아제핀 유도체의 용도
JP2020530448A (ja) 2017-08-09 2020-10-22 アルビレオ・アクチボラグ コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
CN110996915B (zh) 2017-08-09 2023-10-03 阿尔比里奥公司 考来烯胺丸粒、口服考来烯胺制剂及其用途
MX2020009332A (es) 2018-03-09 2020-10-08 Elobix Ab Proceso para la preparacion de elobixibat.
JP7391048B2 (ja) 2018-06-05 2023-12-04 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
MX2020013839A (es) 2018-06-20 2021-03-25 Albireo Ab Formulacion farmaceutica de odevixibat.
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
RS63899B1 (sr) 2019-02-06 2023-02-28 Albireo Ab Benzotiadiazepinska jedinjenja i njihova upotreba kao modulatora žučnih kiselina
TWI835997B (zh) * 2019-02-06 2024-03-21 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其用作膽酸調節劑之用途
CA3129826A1 (en) 2019-02-12 2020-08-20 Mirum Pharmaceuticals, Inc. Methods for treating cholestasis
WO2021049311A1 (ja) 2019-09-09 2021-03-18 エロビクス・アーベー １，５－ベンゾチアゼピン化合物を製造するための方法
WO2021110887A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
AR120679A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar
AR120682A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar
WO2021110886A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP4069359B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP7665620B2 (ja) 2019-12-04 2025-04-21 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
TWI867107B (zh) 2019-12-04 2024-12-21 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
BR112022010505A2 (pt) 2019-12-04 2022-09-06 Albireo Ab Compostos de benzotia(di)azepina e seu uso como moduladores do ácido biliar
CA3186857A1 (en) 2020-08-03 2022-02-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022101379A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
AU2021390172A1 (en) 2020-12-04 2023-06-22 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
CN119343140A (zh) 2022-06-09 2025-01-21 阿尔比里奥公司 治疗肝炎
JP2025521736A (ja) * 2022-07-05 2025-07-10 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CN120379676A (zh) 2022-11-03 2025-07-25 阿尔比里奥公司 治疗阿拉杰里综合征(algs)
AU2024369988A1 (en) 2023-11-03 2026-04-09 Albireo Ab Treating pfic2 with odevixibat
WO2025146508A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146507A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203347D0 (en) 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
IL108633A (en) 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA956647B (en) 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
BR9508916A (pt) 1994-09-13 1997-12-30 Monsanto Co "Novas benzotiepinas tendo atividade como inibidores de transporte do ácido biliar ileal e absorção de taurocolato"
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
GB9423172D0 (en) 1994-11-17 1995-01-04 Wellcom Foundation The Limited Hypolipidemic benzothiazepines
NZ331813A (en) 1996-03-11 2001-03-30 G Benzothiepine compounds having activity as inhibitors of ileal bile acid transport and taurocholate uptake
GB9704208D0 (en) 1997-02-28 1997-04-16 Glaxo Group Ltd Chemical compounds
NZ337830A (en) 1997-03-11 2001-07-27 G Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
DK0864582T3 (da) 1997-03-14 2003-09-29 Aventis Pharma Gmbh Hypolidemiske 1,4-benzothiazepin-1,1-dioxider
GB2338810B (en) 1997-12-31 2001-09-12 Infodream Corp Bubble edit
GB9800428D0 (en) * 1998-01-10 1998-03-04 Glaxo Group Ltd Chemical compounds
DE19825804C2 (de) 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
CN1342091A (zh) 1998-12-23 2002-03-27 G.D.瑟尔有限公司 心血管指征的联合用药
EP1342475A1 (en) 1998-12-23 2003-09-10 G.D. Searle LLC. Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
KR20010102963A (ko) 1998-12-23 2001-11-17 윌리암스 로저 에이 심장 혈관 징후를 위한 회장 담즙산 수송 저해제와니코틴산 유도체의 조합물
PT1140190E (pt) 1998-12-23 2003-02-28 Searle Llc Combinacoes de inibidores do transporte ileal dos acidos biliares e agentes sequestrantes dos acidos biliares usadas para problemas cardiovasculares
MXPA01006472A (es) 1998-12-23 2004-03-10 Searle Llc Combinaciones de inhibidores de transporte de acido biliar ileal y derivados de acido fibrico para indicaciones cardiovasculares.
CA2362147A1 (en) 1999-02-12 2000-08-17 Steve A. Kolodziej 1,2-benzothiazepines for the treatment of hyperlipidemic diseases
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
SE9901387D0 (sv) 1999-04-19 1999-04-19 Astra Ab New pharmaceutical foromaulations
EP1259494A4 (en) 2000-02-18 2004-09-15 Merck & Co Inc ARYLOXYACETIC ACIDS FOR DIABETES AND LIPID DISORDERS
EP1286984A2 (en) 2000-03-10 2003-03-05 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
WO2001068096A2 (en) 2000-03-10 2001-09-20 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US20020183307A1 (en) 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
SE0003766D0 (sv) 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
PL216023B1 (pl) 2001-09-08 2014-02-28 Astrazeneca Ab Pochodna benzotiadiazepiny, kompozycja farmaceutyczna zawierajaca pochodna benzotiadiazepiny oraz zastosowania pochodnej benzotiadiazepiny

Also Published As

Publication number Publication date
KR20020079990A (ko) 2002-10-21
ATE283266T1 (de) 2004-12-15
NO20024217D0 (no) 2002-09-04
EP1263747B1 (en) 2004-11-24
JP5204361B2 (ja) 2013-06-05
DE60107395D1 (de) 2004-12-30
IL151296A0 (en) 2003-04-10
SE0000772D0 (sv) 2000-03-08
MXPA02008600A (es) 2003-02-24
ZA200206739B (en) 2003-11-24
CN1416425A (zh) 2003-05-07
WO2001066533A1 (en) 2001-09-13
US20030166927A1 (en) 2003-09-04
NZ520951A (en) 2004-05-28
JP2003525933A (ja) 2003-09-02
CA2401055A1 (en) 2001-09-13
EP1263747A1 (en) 2002-12-11
AU2001237556B2 (en) 2004-10-07
DE60107395T2 (de) 2005-12-01
NO20024217L (no) 2002-10-09
AU3755601A (en) 2001-09-17
US6906058B2 (en) 2005-06-14

Similar Documents

Publication Publication Date Title
BR0309493A (pt) Composto, processo para preparar um composto, uso de um composto, método para produzir um efeito inibidor de ibat em um animal de sangue quente, e, composição farmacêutica
BR0212344A (pt) Composto, processo para preparar um composto, uso de um composto, método para produzir um efeito inibidor de ácido de bile ileal em um animal de sangue quente e composição farmacêutica
BR0116397A (pt) Composto, processo para preparar o mesmo, uso de um composto, método para produzir um efeito inibidor de ibat em um animal de sangue quente, e, composição farmacêutica
BR0212346A (pt) Composto ou um sal farmaceuticamente aceitável, solvato, solvato deste sal ou uma pró-droga do mesmo, processo para a preparação do mesmo, uso deste, método para produzir um efeito inibidor de ibat em um animal de sangue quente, como um humano, em necessidade deste tratamento, e, composição farmacêutica
SE0000772D0 (sv) Chemical compounds
BR0311628A (pt) Composto, processo para preparar e uso do mesmo, método para produzir um efeito inibitório do ibat em um animal de sangue quente, e, composição farmacêutica
BR0212277A (pt) Composto, processo para preparar um composto, uso de um composto, método para produzir um efeito inibidor do ibat, e, composição farmacêutica
BR0212345A (pt) Composto, processo para preparar um composto, uso de um composto, método para produzir um efeito inibidor de ácido de bile ileal em um animal de sangue quente e composição farmacêutica
ATE193888T1 (de) Nicht-steroidale sulfatase hemmer verbindungen
BRPI0414111A (pt) inibidores heterocìclicos de mek e métodos de uso dos mesmos
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
ATE460394T1 (de) 5-asa-derivate mit entzündungshemmender und antibiotischer wirkung und verfahren zur behandlung von krankheiten mit diesen derivaten
ES2135695T3 (es) Derivados de aminoacidos y su uso como inhibidores de la fosfolipasa a2.
DK601683A (da) Dialkylaminoalkoxybenzylalkoholderivater
AR029001A1 (es) Derivados de bencil-3,4-metilendioxicinamico y el uso de los mismos para la manufactura de un medicamento
ATE316525T1 (de) Neue desloratadinsalze, verfahren zu deren synthese und diese enthaltende pharmazeutische zusammensetzungen
EA200101109A1 (ru) Производные 1-трифторметил-4-гидрокси-7-пиперидинил-аминометилхромана
ATE28632T1 (de) Piperidin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ES528459A0 (es) Procedimiento de preparacion de nuevos derivados 1-hidroxipropil resorcinos provistos de un grupo fenilo sustituidos.
ATE29251T1 (de) Aminopyridincarbonsaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1963 DE 19.08.2008.